( MENAFN - GlobeNewsWire - Nasdaq) IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centres BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the National Institute for Health and Care Excellence (NICE) has issued guidance that recommends IMCIVREE® (setmelanotide) as an option for treating obesity and the control of hunger (hyperphagia) in genetically confirmed Bardet-Biedl syndrome (BBS) in people 6 years of age and over, if they are between 6 and 17 years of age when treatment starts. Patients may remain on reimbursed setmelanotide as adults whilst they continue to benefit from therapy.
“Access to IMCIVREE in England and Wales is an important milestone in our global efforts to bring this medicine to patients and families with BBS,” said Yann Mazabraud, Executive Vice President, Head of International at Rhythm Pharmaceuticals.“We are pleased with this positive recommendation from NICE, made possible by the collaboration and support of advocacy leaders at BBS U.K.
and clinical experts, and engaging and productive discussions with NICE.” BBS is a rare genetic disease with an estimated prevalence of approximately 900 patients in England and Wales. People living with BB.